These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 19923011)

  • 1. Serum levels of complement C4 fragments correlate with disease activity in multiple sclerosis: proteomic analysis.
    Sawai S; Umemura H; Mori M; Satoh M; Hayakawa S; Kodera Y; Tomonaga T; Kuwabara S; Nomura F
    J Neuroimmunol; 2010 Jan; 218(1-2):112-5. PubMed ID: 19923011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls.
    Liu J; Yin L; Dong H; Xu E; Zhang L; Qiao Y; Liu Y; Li L; Jia J
    J Neuroimmunol; 2012 Sep; 250(1-2):71-6. PubMed ID: 22633274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The levels of C3 and C4 components of the complement in the sera of relapsing-remitting multiple sclerosis patients (RR-MS) treated by 2-CDA (cladribine).
    Bartosik-Psujek H; Stelmasiak Z; Mitosek-Szewczyk K; Belniak-Legieć E; Dobosz B
    Ann Univ Mariae Curie Sklodowska Med; 2000; 55():231-4. PubMed ID: 11482079
    [No Abstract]   [Full Text] [Related]  

  • 4. Spiking of serum specimens with exogenous reporter peptides for mass spectrometry based protease profiling as diagnostic tool.
    Findeisen P; Peccerella T; Post S; Wenz F; Neumaier M
    Rapid Commun Mass Spectrom; 2008 Apr; 22(8):1223-9. PubMed ID: 18348224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteomic pattern analysis discriminates among multiple sclerosis-related disorders.
    Komori M; Matsuyama Y; Nirasawa T; Thiele H; Becker M; Alexandrov T; Saida T; Tanaka M; Matsuo H; Tomimoto H; Takahashi R; Tashiro K; Ikegawa M; Kondo T
    Ann Neurol; 2012 May; 71(5):614-23. PubMed ID: 22522477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis.
    Nanni P; Parisi D; Roda G; Casale M; Belluzzi A; Roda E; Mayer L; Roda A
    Rapid Commun Mass Spectrom; 2007; 21(24):4142-8. PubMed ID: 18022963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach.
    de Seny D; Fillet M; Meuwis MA; Geurts P; Lutteri L; Ribbens C; Bours V; Wehenkel L; Piette J; Malaise M; Merville MP
    Arthritis Rheum; 2005 Dec; 52(12):3801-12. PubMed ID: 16320331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity.
    Sternberg Z; Weinstock-Guttman B; Hojnacki D; Zamboni P; Zivadinov R; Chadha K; Lieberman A; Kazim L; Drake A; Rocco P; Grazioli E; Munschauer F
    Mult Scler; 2008 Jul; 14(6):759-63. PubMed ID: 18505774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of serum proteomes: discovery of proteins associated with osteonecrosis of the femoral head.
    Tan X; Cai D; Wu Y; Liu B; Rong L; Chen Z; Zhao Q
    Transl Res; 2006 Sep; 148(3):114-9. PubMed ID: 16938648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery.
    Koomen JM; Li D; Xiao LC; Liu TC; Coombes KR; Abbruzzese J; Kobayashi R
    J Proteome Res; 2005; 4(3):972-81. PubMed ID: 15952745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF proteome analysis in clinically isolated syndrome (CIS): candidate markers for conversion to definite multiple sclerosis.
    Tumani H; Lehmensiek V; Rau D; Guttmann I; Tauscher G; Mogel H; Palm C; Hirt V; Suessmuth SD; Sapunova-Meier I; Ludolph AC; Brettschneider J
    Neurosci Lett; 2009 Mar; 452(2):214-7. PubMed ID: 19383442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling.
    Findeisen P; Zapatka M; Peccerella T; Matzk H; Neumaier M; Schadendorf D; Ugurel S
    J Clin Oncol; 2009 May; 27(13):2199-208. PubMed ID: 19307507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased serum levels of soluble CD14 indicate stable multiple sclerosis.
    Lutterotti A; Kuenz B; Gredler V; Khalil M; Ehling R; Gneiss C; Egg R; Deisenhammer F; Berger T; Reindl M
    J Neuroimmunol; 2006 Dec; 181(1-2):145-9. PubMed ID: 17046070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
    Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
    Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cerebrospinal fluid proteome profile in multiple sclerosis.
    Lehmensiek V; Süssmuth SD; Tauscher G; Brettschneider J; Felk S; Gillardon F; Tumani H
    Mult Scler; 2007 Aug; 13(7):840-9. PubMed ID: 17881397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted comparative proteomics by liquid chromatography/matrix-assisted laser desorption/ionization triple-quadrupole mass spectrometry.
    Melanson JE; Chisholm KA; Pinto DM
    Rapid Commun Mass Spectrom; 2006; 20(5):904-10. PubMed ID: 16470697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry on identifing biomarkers of endometriosis.
    Zhang H; Feng J; Chang XH; Li ZX; Wu XY; Cui H
    Chin Med J (Engl); 2009 Feb; 122(4):373-6. PubMed ID: 19302738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum anti-Glc(alpha1,4)Glc(alpha) antibodies as a biomarker for relapsing-remitting multiple sclerosis.
    Schwarz M; Spector L; Gortler M; Weisshaus O; Glass-Marmor L; Karni A; Dotan N; Miller A
    J Neurol Sci; 2006 May; 244(1-2):59-68. PubMed ID: 16480743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel approach using MALDI-TOF/TOF mass spectrometry and prestructured sample supports (AnchorChip Technology) for proteomic profiling and protein identification.
    Leung SM; Pitts RL
    Methods Mol Biol; 2008; 441():57-70. PubMed ID: 18370311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.